Alexion Pharma

Wilson Therapeutics is a biopharmaceutical company based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in oncology and Wilson's disease, as well as some other clinical pathologies.

Wilson Therapeutics

Synageva was a publicly listed biopharmaceutical company headquartered in Lexington, Massachusetts dedicated to discovering, developing and delivering medicines for patients with rare diseases and high unmet medical needs. The company had manufacturing and laboratory locations in Lexington and Holden, Massachusetts, Bogart and Athens Georgia, as well as offices in a variety of locations around the world.

Synageva

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).  In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

WILMINGTON, Del., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Alexion Pharmaceuticals, Inc. (“Alexion”) (NASDAQ GS: ALXN) regarding possible breaches of fiduciary duties and other violations of law related to Alexion's agreement to be acquired by AstraZeneca PLC (“AstraZeneca”) (NASDAQ GS: AZN). Under the terms of the agreement, Alexion's shareholders will receive 2.1243 American Depository Shares of AstraZeneca and $60.00 in cash per share.

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Alexion Pharmaceuticals, Inc. Buyout

NEW YORK, Dec. 14, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (NASDAQ: ALXN) in connection with the proposed acquisition of the...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Alexion Pharmaceuticals, Inc.

PayPal

The Nasdaq Composite looked to get back into record territory on Monday.

Alexion Lifts Nasdaq on Buyout News; PayPal Gets Bitcoin Boost

AstraZeneca

Alexion (ALXN) is set to be acquired by AstraZeneca for $39 billion or $175 per share. The acquisition is expected to close in the third quarter of 2021.

Alexion (ALXN) to Be Acquired by AstraZeneca for $39 Billion

Over the weekend, AstraZeneca made a $39 billion offer to acquire Alexion Pharmaceuticals in a deal that looks like it will benefit both parties.

AstraZeneca: Starting The Acquisition Boom

Why Alexion Pharmaceuticals Is Soaring and AstraZeneca Is Sinking Today

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) shares shot up on Monday after it was announced over the weekend that the company would be acquired by AstraZeneca PLC (NASDAQ: AZN).

What This Alexion Acquisition Means for AstraZeneca

Late last week, AstraZeneca said that it would acquire Alexion Pharmaceuticals - a company best known for its Soliris and Ultomiris drugs - in a cash and stock deal valued at about $39 billion. There are a couple of sound reasons for this deal, as we detail below.

Why AstraZeneca Wants To Buy Alexion Pharmaceuticals

The two companies announced on Saturday that they had reached a deal valuing Alexion at $39 billion.

The Alexion Takeover Is A Major Expansion For AstraZeneca. Why The Stock Is Down 7%

AstraZeneca (AZN) agrees to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest M&A deal ever.

AstraZeneca (AZN) Stock Down on $39B Offer to Buy Alexion

AstraZeneca has agreed to buy U.S. Alexion Pharmaceuticals for $39 billion, betting on rare diseases and immunology as the British drug company emerges as one of the leading developers of a COVID-19 vaccine.

AstraZeneca will acquire Alexion Pharmaceuticals in $39 billion push into rare diseases and immunology

Alexion Pharmaceuticals soared 35% in pre-market trading on Monday after AstraZeneca announced a $39 billion acquisition of the Boston-based drugmaker. The deal was approved by both boards unanimously and is expected to close in the third quarter of 2021. Alexion shareholders will own about 15% of the combined company. Two members from Alexion's board move to AstraZeneca's board.

Alexion Pharmaceuticals soars 35% after AstraZeneca agrees to $39 billion takeover

Shares of AstraZeneca fell 8% early on Monday, hit by doubts about the British firm's strategy and speculation of a rival bid after it announced the $39 billion purchase of Alexion Pharmaceuticals over the weekend.

AstraZeneca shares sink 8% after $39 billion Alexion buyout

SAN DIEGO, Dec. 13, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (NASDAQ: ALXN) breached their fiduciary duties in connection with the...

(ALXN): Johnson Fistel Investigates Proposed Sale of Alexion Pharmaceuticals; Are Shareholders Getting a Fair Deal?

AstraZeneca plc (NASDAQ: AZN) announced it is buying Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) for $39 billion in cash and shares. These are the details.

Why AstraZeneca (AZN) Is Buying Alexion (ALXN) For $39 Billion

AstraZeneca has announced its acquiring Alexion at a fairly substantial 45% premium. It's a mixed stock - cash offer. The synergies will cover most of the ~$900 million in annual dividend / interest costs with significant growth potential.

The Next Major Pharmaceutical Acquisition Is Here

AstraZeneca plc (LON: AZN) said on Saturday that it will buy Alexion Pharmaceuticals (NASDAQ: ALXN) for £29.50 billion. The acquisition marks the largest for the British pharmaceutical giant in history.

AstraZeneca to acquire Alexion Pharmaceuticals for £29.50 billion

At $39 billion, AstraZeneca is low-balling its bid for Alexion -- maker of Soliris, a drug that sells for $678,302 a year

AstraZeneca To Pay $39B For Alexion — 14% Off Its All-Time High

Leading Covid-19 vaccine developer AstraZeneca agreed on Saturday to buy Boston pharmaceutical firm Alexion for $39 billion.

Covid-19 vaccine developer AstraZeneca agrees to buy rare disease firm Alexion for $39 billion

Alexion shareholders will receive a big premium in a combination of cash and AstraZeneca stock.

AstraZeneca to Buy Alexion Pharmaceuticals for $39 Billion

AstraZeneca plc (NASDAQ: AZN)has announced it will buy Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), a Boston-based drugmaker, for $39 billion. What Happened: British pharmaceutical company AstraZeneca and Boston-based Alexion said this morning that their boards unanimously approved the deal.

AstraZeneca To Buy Rare-Disease Specialist Drugmaker Alexion For $39 Billion

AstraZeneca on Saturday announced it was acquiring Alexion Pharmaceuticals in a $39 billion deal,  a move intended to boost AstraZeneca's immunology research and combine the company's delivery pipelines.  "Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases. This acquisition allows us to enhance our presence in immunology," said Pascal Soriot, chief executive of AstraZeneca, in a joint statement. 

AstraZeneca is acquiring Alexion Pharmaceuticals in a $39 billion pharmaceutical deal

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) to AstraZeneca PLC for $60.00 in cash and 2.1243 AstraZeneca American Depositary Shares for each Alexion share is fair to Alexion shareholders. Halper Sadeh encourages Alexion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.co

Alexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Alexion Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ALXN

AstraZeneca Plc will acquire U.S. based Alexion Pharmaceuticals in a $39 billion deal, the company said in a statement on Saturday.

AstraZeneca to acquire Alexion in $39 billion deal

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--AstraZeneca to acquire Alexion, accelerating the Company's strategic and financial development

News for Alexion Pharma Stock (ALXN)